Cited by 30

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors

Herbrich, Shelley, Chaib, Mehdi, Anandhan, Swetha, Andrewes, Samuel W., Nagarajan, Ashwat, Guan, Baoxiang, Gandhi, Nishant, Gilliam, Jared, Radovich, Milan, Sharma, Padmanee·2026·Cancer Cell

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2025.09.011

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 56

  1. Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, 126, 9, 10.1182/blood-2015-03-631747 · DOI · Paper page
  2. Genovese, 2014, Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence, N. Engl. J. Med., 371, 2477, 10.1056/NEJMoa1409405 · DOI · Paper page
  3. Jaiswal, 2014, Age-related clonal hematopoiesis associated with adverse outcomes, N. Engl. J. Med., 371, 2488, 10.1056/NEJMoa1408617 · DOI · Paper page
  4. Bolton, 2021, Clonal hematopoiesis is associated with risk of severe Covid-19, Nat. Commun., 12, 5975, 10.1038/s41467-021-26138-6 · DOI
  5. Pich, 2025, Tumor-Infiltrating Clonal Hematopoiesis, N. Engl. J. Med., 392, 1594, 10.1056/NEJMoa2413361 · DOI
  6. Kleppe, 2015, Somatic mutations in leukocytes infiltrating primary breast cancers, NPJ Breast Cancer, 1, 10.1038/npjbcancer.2015.5 · DOI
  7. Severson, 2018, Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens, Blood, 131, 2501, 10.1182/blood-2018-03-840629 · DOI
  8. Ptashkin, 2018, Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors, JAMA Oncol., 4, 1589, 10.1001/jamaoncol.2018.2297 · DOI
  9. Bolton, 2020, Cancer therapy shapes the fitness landscape of clonal hematopoiesis, Nat. Genet., 52, 1219, 10.1038/s41588-020-00710-0 · DOI · Paper page
  10. Coombs, 2017, Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes, Cell Stem Cell, 21, 374, 10.1016/j.stem.2017.07.010 · DOI · Paper page
  11. Ko, 2010, Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2, Nature, 468, 839, 10.1038/nature09586 · DOI · Paper page
  12. Figueroa, 2010, Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation, Cancer Cell, 18, 553, 10.1016/j.ccr.2010.11.015 · DOI · Paper page
  13. Calcagno, 2020, The myeloid type I interferon response to myocardial infarction begins in bone marrow and is regulated by Nrf2-activated macrophages, Sci. Immunol., 5, 10.1126/sciimmunol.aaz1974 · DOI
  14. Pan, 2017, The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression, Immunity, 47, 284, 10.1016/j.immuni.2017.07.020 · DOI
  15. Nguyen, 2021, Tet2 deficiency in immune cells exacerbates tumor progression by increasing angiogenesis in a lung cancer model, Cancer Sci., 112, 4931, 10.1111/cas.15165 · DOI
  16. Chisolm, 2019, Defining Genetic Variation in Widely Used Congenic and Backcrossed Mouse Models Reveals Varied Regulation of Genes Important for Immune Responses, Immunity, 51, 155, 10.1016/j.immuni.2019.05.006 · DOI
  17. Grasso, 2020, Conserved Interferon-gamma Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma, Cancer Cell, 38, 500, 10.1016/j.ccell.2020.08.005 · DOI · Paper page
  18. Ishida, 2008, Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function, J. Immunol., 180, 569, 10.4049/jimmunol.180.1.569 · DOI · Paper page
  19. Nalio Ramos, 2022, Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer, Cell, 185, 1189, 10.1016/j.cell.2022.02.021 · DOI
  20. Seyfried, 2021, CCR5 maintains macrophages in the bone marrow and drives hematopoietic failure in a mouse model of severe aplastic anemia, Leukemia, 35, 3139, 10.1038/s41375-021-01219-z · DOI
  21. Lancien, 2021, Dendritic Cells Require TMEM176A/B Ion Channels for Optimal MHC Class II Antigen Presentation to Naive CD4(+) T Cells, J. Immunol., 207, 421, 10.4049/jimmunol.2000498 · DOI
  22. Jenkins, 2025, TET2-loss enhances immediate and time-resolved interferon-gamma signaling responses across myeloid differentiation, Exp. Hematol., 144, 10.1016/j.exphem.2025.104727 · DOI
  23. Plattner, 2020, Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq, Methods Enzymol., 636, 261, 10.1016/bs.mie.2019.05.056 · DOI
  24. Ott, 2019, T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028, J. Clin. Oncol., 37, 318, 10.1200/JCO.2018.78.2276 · DOI · Paper page
  25. Ayers, 2017, IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade, J. Clin. Investig., 127, 2930, 10.1172/JCI91190 · DOI · Paper page
  26. Xu, 2019, Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy, J. Clin. Investig., 129, 4316, 10.1172/JCI129317 · DOI
  27. Peng, 2022, Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma, Int. J. Biol. Sci., 18, 995, 10.7150/ijbs.67329 · DOI
  28. Castro, 2018, Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion, Front. Immunol., 9, 847, 10.3389/fimmu.2018.00847 · DOI · Paper page
  29. Dimitri, 2024, TET2 regulates early and late transitions in exhausted CD8(+) T cell differentiation and limits CAR T cell function, Sci. Adv., 10, 10.1126/sciadv.adp9371 · DOI
  30. Jain, 2023, TET2 guards against unchecked BATF3-induced CAR T cell expansion, Nature, 615, 315, 10.1038/s41586-022-05692-z · DOI
  31. Lee, 2021, Tet2 Inactivation Enhances the Antitumor Activity of Tumor-Infiltrating Lymphocytes, Cancer Res., 81, 1965, 10.1158/0008-5472.CAN-20-3213 · DOI
  32. Heimlich, 2024, Multiomic profiling of human clonal hematopoiesis reveals genotype and cell-specific inflammatory pathway activation, Blood Adv., 8, 3665, 10.1182/bloodadvances.2023011445 · DOI
  33. Niroula, 2021, Distinction of lymphoid and myeloid clonal hematopoiesis, Nat. Med., 27, 1921, 10.1038/s41591-021-01521-4 · DOI
  34. Rauch, 2023, Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypes, Nat. Cardiovasc. Res., 2, 805
  35. Sano, 2018, Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1beta/NLRP3 Inflammasome, J. Am. Coll. Cardiol., 71, 875, 10.1016/j.jacc.2017.12.037 · DOI · Paper page
  36. Fuster, 2020, TET2-Loss-of-Function-Driven Clonal Hematopoiesis Exacerbates Experimental Insulin Resistance in Aging and Obesity, Cell Rep., 33, 10.1016/j.celrep.2020.108326 · DOI · Paper page
  37. Ito, 2019, Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis, Cell Rep., 28, 2480, 10.1016/j.celrep.2019.07.094 · DOI · Paper page
  38. Yeaton, 2022, The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation, Cancer Discov., 12, 2392, 10.1158/2159-8290.CD-21-1146 · DOI · Paper page
  39. Hsiehchen, 2022, Clonal hematopoiesis and differential outcomes after immune checkpoint blockade, Cancer Cell, 40, 1071, 10.1016/j.ccell.2022.08.024 · DOI
  40. Diplas, 2023, Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers, JAMA Netw. Open, 6, 10.1001/jamanetworkopen.2022.54221 · DOI
  41. Svensson, 2022, TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial, JAMA Cardiol., 7, 521, 10.1001/jamacardio.2022.0386 · DOI · Paper page
  42. Boj, 2015, Organoid models of human and mouse ductal pancreatic cancer, Cell, 160, 324, 10.1016/j.cell.2014.12.021 · DOI · Paper page
  43. Bian, 2021, Intratumoral SIRPalpha-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy, Nat. Commun., 12, 3229, 10.1038/s41467-021-23442-z · DOI
  44. Chaib, 2023, Protein kinase C delta regulates mononuclear phagocytes and hinders response to immunotherapy in cancer, Sci. Adv., 9, 10.1126/sciadv.add3231 · DOI
  45. Borcherding, 2021, Mapping the immune environment in clear cell renal carcinoma by single-cell genomics, Commun. Biol., 4, 122, 10.1038/s42003-020-01625-6 · DOI
  46. Tirosh, 2016, Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq, Science, 352, 189, 10.1126/science.aad0501 · DOI · Paper page
  47. Chen, 2016, Cytofkit: A Bioconductor Package for an Integrated Mass Cytometry Data Analysis Pipeline, PLoS Comput. Biol., 12, 10.1371/journal.pcbi.1005112 · DOI
  48. Hahne, 2009, flowCore: a Bioconductor package for high throughput flow cytometry, BMC Bioinf., 10, 106, 10.1186/1471-2105-10-106 · DOI
  49. Van Gassen, 2015, FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data, Cytometry. A., 87, 636, 10.1002/cyto.a.22625 · DOI
  50. Becht, 2018, Dimensionality reduction for visualizing single-cell data using UMAP, Nat. Biotechnol.
  51. Nikolayeva, 2014, edgeR for differential RNA-seq and ChIP-seq analysis: an application to stem cell biology, Methods Mol. Biol., 1150, 45, 10.1007/978-1-4939-0512-6_3 · DOI
  52. Diboun, 2006, Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma, BMC Genom., 7, 252, 10.1186/1471-2164-7-252 · DOI
  53. Love, 2014, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15, 550, 10.1186/s13059-014-0550-8 · DOI · Paper page
  54. Barbie, 2009, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462, 108, 10.1038/nature08460 · DOI
  55. Finotello, 2019, Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data, Genome Med., 11, 34, 10.1186/s13073-019-0638-6 · DOI
  56. Cristescu, 2018, Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy, Science, 362, 10.1126/science.aar3593 · DOI · Paper page

Cited by

Metadata

Authors
Herbrich, S., Chaib, M., Anandhan, S., Andrewes, S. W., Nagarajan, A., Guan, B., Gandhi, N., Gilliam, J., Radovich, M., & Sharma, P.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2026-01
Volume
44
Issue
1
Pages
187-202.e7
ISSN
1535-6108
Cited by
30
References
12
Language
en
Funders
  • National Institutes of Health (1S10OD024977-01)
  • Parker Institute for Cancer Immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review